Background {#Sec1}
==========

Resveratrol (3′,5′,4′-trihydroxystilbene) is a naturally occurring polyphenolic compound that was first isolated from the roots of white Hellebore \[[@CR1]\]. It has been found in various plant roots and also a constituent of red wine \[[@CR2], [@CR3]\]. Studies have shown that resveratrol may have a number of health benefits. Resveratrol has shown potential beneficial effects in cardiovascular disease in preclinical studies. The vasorelaxant activity of resveratrol occurs via activation of adenosine monophosphate activated protein kinase (AMPK), nuclear factor erythroid-2 related factor 2 (NRF2), and silent information regulator 1 (SIRT1) \[[@CR4], [@CR5]\]. In addition, resveratrol has antioxidant, anti-inflammatory, and cytoprotective effects \[[@CR6]\].

Biliary colic is most frequently associated with obstruction caused by gallstone impaction in the cystic duct or the common bile duct. If the biliary duct obstruction persists, the gallbladder becomes inflamed. Medical treatment of biliary colic includes nonsteroidal anti-inflammatory drugs (NSAIDs) such as ketorolac and diclofenac, as well as anti-cholinergic drugs such as scopolamine or propantheline \[[@CR7], [@CR8]\]. However, NSAIDs usually induce peptic ulcers or gastrointestinal upset, and common side effects of anti-cholinergic drugs include urinary retention, glaucoma, and confusion \[[@CR9]\].

Although resveratrol produces relaxation of the guinea pig gallbladder muscle, there is limited data concerning the effect of resveratrol on the gallbladder smooth muscle in humans \[[@CR10], [@CR11]\]. The objective of this study was to investigate the effect of resveratrol in human gallbladder smooth muscle and the underlying mechanism.

Methods {#Sec2}
=======

Tetraethylammonium (TEA) was purchased from Santa Cruz Biotech, California, USA. Iberiotoxin was purchased from Alomone, Jerusalem, Israel. Glibenclamide was purchased from Research Biochemical International, Massachusetts, USA. Tetrodotoxin (TTX) was purchased from Tocris Bioscience, Bristol, UK. ω-conotoxin GVIA (CTX) was purchased from Bachem, Bubendorf, Switzerland. KT 5720, KT 5823, NG-Nitro-L-arginine (L-NNA), apamine, papaverine, and resveratrol were obtained from Sigma-Aldrich, Missouri, USA. Charybdotoxin was purchased from AnaSpec Inc., California, USA.

The effects of resveratrol in human gallbladder {#Sec3}
-----------------------------------------------

All procedures were performed in accordance with relevant laws and institutional guidelines. In addition, the Institutional Review Board / Ethics Committee of Tzu Chi Hospital approved the protocol for this work (approval number: IRB097-55). The human specimens of gallbladder were acquired from patients undergoing cholecystectomy for gallstone (excluding acute cholecystitis) or hepatoma, and informed consent was obtained from every patient. Human gallbladder specimens were acquired from 39 patients (The ratio of male to female was 22:17; the age range was from 28 to 80 years; the median age was 58 years; the mean age was 56.8 ± 1.9 years). A standard incubation solution was made up of the following composition (in mM): 118 NaCl, 25 NaHCO~3~, 4.7 KCl, 14 glucose, 1.2 NaH~2~PO~4~, 1.8 CaCl~2~, pH 7.4. Immediately after surgical removal of the gallbladder, an area of 3 × 5 cm was excised from the middle portion of each gallbladder corpus. The human specimens were placed in oxygenated standard incubation solution gassed with 95% O~2~ + 5% CO~2~ for transportation to the laboratory, where the relaxation experiment was at once initiated. The period of transportation was less than 30 min. The human gallbladder strips were used to study the effects of resveratrol on gallbladder. The muscle strips, which were 3 mm wide and 10 mm long, were trimmed and hanged in 7 ml organ baths containing a standard incubation solution, incubated at 37 °C, and continuously gassed with 95% O~2~ + 5% CO~2~. Subsequently, the muscle strips were joined to isometric force transducers (FT.03; Grass Technologies, West Warwick, RI, USA), which were linked to amplifiers and a computer recording system (BIOPAC Systems, CA, USA). The basal tension of the muscle strips was set at 1.0 g. After a 30 min equilibration period, carbachol (1 μM) was added into the organ bath, the muscle strip contractions were measured, and the carbachol was washed out. For measurements of relaxation in carbachol-precontracted strips, resveratrol was added to muscle strips 15 min after the addition of carbachol. Resveratrol was added in a noncumulative fashion, i.e., with single dose administration (1 μM, 10 μM, 30 μM, 100 μM, or 1 mM, n is at least ≥4), and the isolated gallbladder muscle strip relaxations were measured. After the final step of the experiments, papaverine (100 μM) was added, and the muscle strip relaxations were measured. The difference between papaverine-induced relaxation and carbachol-induced contraction served as a reference (100%) for the relaxation response to resveratrol.

The effects of resveratrol on neurally-mediated human gallbladder relaxation {#Sec4}
----------------------------------------------------------------------------

In order to determine whether resveratrol triggers neurally-mediated human gallbladder relaxation, 1 μM TTX (a neuronal Na^+^ channel blocker) and 1 μM CTX (a neuronal Ca^2+^ channel blocker) were added 15 min before the addition of 100 μM resveratrol to test the effects of resveratrol on neurally-mediated human gallbladder relaxation.

The effects of cAMP, cGMP and nitric oxide (NO) on resveratrol-induced human gallbladder relaxation {#Sec5}
---------------------------------------------------------------------------------------------------

In order to investigate the mechanism of resveratrol-induced human gallbladder relaxation, 1 μM KT 5720 (a cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA) inhibitor), 1 μM KT 5823 (a cyclic guanosine monophosphate (cGMP)-dependent protein kinase (PKG) inhibitor), and 100 μM L-NNA (a competitive nitric oxide synthase (NOS) inhibitor) were added 30 min before the addition of 100 μM resveratrol to test the involvement of cAMP, cGMP, and NO on resveratrol-induced human gallbladder relaxation \[[@CR12], [@CR13]\].

The effects of potassium channel antagonists on resveratrol-induced human gallbladder relaxation {#Sec6}
------------------------------------------------------------------------------------------------

In order to investigate whether potassium channels are involved in resveratrol-induced human gallbladder relaxation, 1 mM TEA (a non-selective potassium channel blocker), 200 nM iberiotoxin (an inhibitor of large conductance calcium-activated potassium (BKCa) channels), 100 nM charybdotoxin, 200 nM apamine, and 10 μM glibenclamide (an adenosine triphosphate (ATP)-sensitive potassium channel blocker) were added 30 min before the addition of 100 μM resveratrol to test the effects of potassium channels on resveratrol-induced human gallbladder relaxation \[[@CR14]--[@CR17]\].

Data analysis {#Sec7}
-------------

Results are expressed as the means ± SEMs. Sample size is at least ≥3 in each subgroup. Statistical evaluation was applied using Student's t-test or one-way analysis of variance (ANOVA), followed by Dunnett's test. *P* \< 0.05 was considered statistically significant.

Results {#Sec8}
=======

The effects of resveratrol in human gallbladder {#Sec9}
-----------------------------------------------

In muscle strips isolated from human gallbladder specimens, 1 μM carbachol induced a marked and long-duration muscle contraction and 1 mM resveratrol induced an obvious muscle relaxation of the carbachol precontracted gallbladder strips (Fig. [1](#Fig1){ref-type="fig"}). The resveratrol-induced relaxation in human gallbladder was dose-dependent (Fig. [2](#Fig2){ref-type="fig"}). Resveratrol caused detectable relaxation of human gallbladder muscle strips at 10 μM and maximal relaxation at 1 mM. The maximal relaxation caused by 1 mM resveratrol was 90.8 ± 5.1% (*n* = 6) of the relaxation caused by 100 μM papaverine.Fig. 1Typical relaxant tracings of human gallbladder muscle strips induced by resveratrol. The arrows indicate the addition of carbachol, resveratrol and dimethyl sulfoxide (DMSO) Fig. 2The ability of resveratrol or dimethyl sulfoxide (vehicle) to induce relaxation of human gallbladder muscle strips. Resveratrol-induced relaxation in the human gallbladder muscle fiber in a dose-dependent manner. The values are expressed as a percent of a papaverine (100 μM)-induced relaxation. The results given are from at least four experiments. The vertical bars represent ± standard error of the mean (SEM). \* represents a significant difference compared with the relaxation induced by resveratrol (*p* \< 0.05)

The effects of resveratrol on neurally-mediated human gallbladder relaxation {#Sec10}
----------------------------------------------------------------------------

As shown in Fig. [3](#Fig3){ref-type="fig"}, neither 1 mM TTX nor 1 mM CTX had inhibitory effects on the relaxation in human gallbladder induced by resveratrol (*p* \> 0.05, *n* = 6 and 3, respectively). These results indicate that resveratrol-induced human gallbladder relaxation does not involve the activation of the enteric nervous system.Fig. 3The effects of tetrodotoxin (TTX) and ω-conotoxin GVIA (CTX) on resveratrol-induced relaxation in the human gallbladder. TTX (1 μM) and CTX (1 μM) had no significant effect on resveratrol-induced relaxation of human gallbladder muscle strips. The results shown are from at least three experiments. The vertical bars represent ± standard error of the mean (SEM)

The effects of cAMP, cGMP and NO on resveratrol-induced human gallbladder relaxation {#Sec11}
------------------------------------------------------------------------------------

As shown in Fig. [4](#Fig4){ref-type="fig"}, 1 μM KT 5720 (*n* = 6) had no inhibitory effects on the relaxation in human gallbladder induced by 100 μM of resveratrol (*p* \> 0.05). However, both 1 μM KT 5823 and 100 μM L-NNA had significant inhibitory effects on resveratrol-induced human gallbladder relaxation (*p* \< 0.05, *n* = 5 and 6 respectively). These results indicate that the relaxation in human gallbladder induced by resveratrol is associated with cGMP and NO production.Fig. 4The effects of KT 5720, KT 5823, and NG-nitro-L-arginine (L-NNA) on resveratrol-induced relaxation in the human gallbladder. KT 5720 (1 μM) had no significant effect on resveratrol-induced relaxation of human gallbladder muscle strips (*p* \> 0.05, *n* = 6). In contrast, L-NNA (100 μM) and KT 5823 (1 μM) exerted significant inhibitory effects on resveratrol-induced relaxation of human gallbladder muscle strips (*p* \< 0.05, *n* = 6). The vertical bars represent ± standard error of the mean (SEM)

The effects of potassium channel antagonists on resveratrol-induced human gallbladder relaxation {#Sec12}
------------------------------------------------------------------------------------------------

As shown in Fig. [5](#Fig5){ref-type="fig"}, 1 mM TEA (*n* = 5) and 200 nM apamine (*n* = 4) did not inhibit the relaxation in human gallbladder induced by 10 μM of resveratrol (*p* \> 0.05, *n* = 12 in the resveratrol group). However, 100 nM charybdotoxin (*n* = 5) had a trend to inhibit relaxation in human gallbladder induced by 10 μM of resveratrol (*p* = 0.093). Furthermore, 10 μM of glibenclamide (*n* = 6) and 200 nM iberiotoxin (*n* = 6) induced a significant inhibitory effect on resveratrol-induced human gallbladder relaxation (*p* \< 0.05). These results indicate that the relaxant effects in human gallbladder induced by resveratrol are related to ATP-sensitive potassium channels and BKCa channels.Fig. 5The effects of tetraethylammonium (TEA), charybdotoxin, apamine, iberiotoxin, and glibenclamide on resveratrol-induced relaxation in the human gallbladder. TEA (1 mM), apamine (100 nM), and charybdotoxin (100 nM) had no significant effect on resveratrol-induced relaxation of human gallbladder muscle strips (*p* \> 0.05, *n* ≥ 4). In contrast, iberiotoxin (200 nM) and glibenclamide (10 μM) significantly inhibited resveratrol-induced relaxation of human gallbladder muscle strips (*p* \< 0.05, *n* = 7). The vertical bars represent ± standard error of the mean (SEM)

Discussion {#Sec13}
==========

The relaxation process of smooth muscle is associated with a decreased concentration of intracellular calcium and increased activity of myosin light chain phosphatase. In addition, the relaxation of smooth muscle is regulated by many signaling pathways, including NO, cAMP, cGMP, and K^+^ channels \[[@CR18]\].

Previous studies have shown that resveratrol-induced vasorelaxant activity was mainly associated with NO and potassium channels \[[@CR19]--[@CR21]\]. In this study, we showed that resveratrol can induce human gallbladder muscle fiber relaxation in a dose-dependent manner and we also investigated the mechanisms of resveratrol-induced relaxation in human gallbladder.

TTX is a selective blocker of neuronal Na^+^ channels, and CTX is a blocker of neuronal Ca^2+^ channels. In order to determine whether resveratrol triggers neurally-mediated human gallbladder relaxation, the effects of TTX and CTX on resveratrol-induced relaxation of the gallbladder were examined in this study. TTX and CTX did not inhibit the resveratrol-induced relaxation in human gallbladder. These results suggested that resveratrol-induced relaxation in human gallbladder is not involved in neurally-mediated human gallbladder relaxation.

In addition, L-NNA is a competitive NOS inhibitor and can suppress neuronal NOS (nNOS) and endothelial NOS (eNOS) \[[@CR22], [@CR23]\]. L-NNA was applied to investigate whether resveratrol affects the nNOS of the neuron or eNOS expressed in smooth muscle cells, ultimately leading to relaxation. Resveratrol-induced relaxation in human gallbladder was inhibited by L-NNA, indicating that resveratrol-induced relaxation in human gallbladder is mediated either by the nNOS in nitrergic nerves in the gallbladder or eNOS expressed in smooth muscle cells or both \[[@CR24]--[@CR26]\]. KT 5823 is an inhibitor of PKG, and KT 5720 is an inhibitor of PKA. KT 5823 inhibited resveratrol-induced relaxation in human gallbladder. However, KT 5720 was unable to inhibit resveratrol-induced relaxation in human gallbladder. These results suggested that resveratrol-induced relaxation in human gallbladder is related to PKG, but not PKA pathway.

The activation of membrane K^+^ channels leads to hyperpolarization of the plasma membrane and further suppresses Ca^2+^ influx into the cell, giving rise to relaxation of smooth muscle \[[@CR27]\]. Charybdotoxin is an inhibitor of BKCa channels and slowly inactivating voltage-gated potassium channels, iberiotoxin is an inhibitor of BKCa channels, apamine is a selective inhibitor of small conductance calcium-activated potassium channels, TEA is a non-selective inhibitor of potassium channel, and glibenclamide is an inhibitor of ATP-sensitive potassium channel \[[@CR14]--[@CR17]\]. Our results show that both glibenclamide and iberiotoxin can significantly inhibit resveratrol-induced relaxation in human gallbladder, indicating that resveratrol affects ATP-sensitive potassium channels and BKCa channels to facilitate resveratrol-induced relaxant pathways in human gallbladder. In addition, ATP-sensitive potassium channels are connected with the resveratrol-induced relaxation of the human umbilical vein and the rat corpus cavernosum \[[@CR28], [@CR29]\].

Resveratrol-induced relaxation of cholecystokinin octapeptide- or KCl-induced tension in guinea pig gallbladder strips mainly occurs via the L-type Ca^2+^ channels \[[@CR10]\]. The difference of resveratrol-induced relaxation mechanisms between the guinea pig and human gallbladders might be affected by different contractile stimulants and species, and more studies are needed to clarify the difference between them.

Conclusions {#Sec14}
===========

In conclusion, the present study showed that resveratrol-induced relaxation of gallbladder occurs through NO, ATP-sensitive potassium channel, and large conductance calcium-activated potassium channel pathways. These results suggest that resveratrol is a potential new drug in the treatment of biliary colic or other gastrointestinal colicky pain.
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